Compounding is a method of mixing, combines or alters\ningredients of a drug to manufacture a medication custom made to the needs to\nindividual patient under the supervision of licensed pharmacist, or a licensed\nphysician or an outsourcing facility.<\/p>\n\n\n\n
Compounded drugs are not FDA-approved. FDA does not check\nthese drugs to assess their safety or efficiency before they reach patients. It\nis only the responsibility of State board of pharmacy to monitor state-licensed\npharmacies that compound drugs in accordance with regulation of section 503A of\nthe FD&C, although FDA has some control over their operations.<\/p>\n\n\n\n
Outsourcing f<\/a>a<\/a>cilities<\/a> registered under section 503B are regulated by FDA and must stratify cGMP requirements and will be inspected by FDA.<\/p>\n\n\n\n An outsourcing facility is geographic location or address\nwhere the drugs are compounded. An outsourcing facility has to be in compliance\nwith section 503B and must comply with cGMP requirements.<\/p>\n\n\n\n If an outsourcing facility engages in compounding non-sterile drugs and animal drugs, mixing, diluting or repacking biological products do not need to register as an outsourcing facility as the drugs compounded are not eligible for exemption form 503B for FD&C act. <\/p>\n\n\n\n All Outsourcing facilities that engages in compounding sterile human drugs needs to register with FDA using CEDR system.<\/p>\n\n\n\n All outsourcing facilities must renew their registration between Oct 1st<\/sup> and Dec 31st<\/sup> and pay the annual establishment registration<\/a> fees for every year as long as they wish to register as an outsourcing facility.<\/p>\n\n\n\n PRODUCT REPORTING PROCEDURES<\/strong><\/p>\n\n\n\n The drug products manufactured from December 1 through May\n31 must submit drug product reporting between June 1 and June 30. In the same\nway, the drug products manufactured from June 1 through November 30 must submit\ndrug product reporting between December 1 and December 30.<\/p>\n\n\n\n Each product report must include all sterile and non-sterile drug compounded in the outsourcing facility must include active ingredient and its strength, NDC number<\/a> of source drug or bulk active ingredient, dosage and route of administration, package description, number of individual units manufactured and NDC number<\/a> of end product (If assigned)<\/p>\n\n\n\n LMG provide assistance with FDA registration <\/a>of Outsourcing facilities.<\/p>\n\n\n\n Sudha S<\/p>\n\n\n\n Regulatory Consultant<\/p>\n\n\n\n Mail \u2013 office@libertymanagement.us<\/p>\n\n\n\n http:\/\/www.fdahelp.us<\/a><\/p>\n\n\n\n Published on: January 9, 2019<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Compounding is a method of mixing, combines or alters ingredients of a drug to manufacture a medication custom made to the needs to individual patient under the supervision of licensed pharmacist, or a licensed physician or an outsourcing facility. Compounded drugs are not FDA-approved. FDA does not check these drugs to assess their safety or … Continue reading “COMPOUNDING PHARMACY REGISTRATION”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[3,2],"class_list":["post-13","post","type-post","status-publish","format-standard","hentry","category-fda-registration-drug","tag-compounding-pharmacy-registration","tag-fda-registration"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/13","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=13"}],"version-history":[{"count":2,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/13\/revisions"}],"predecessor-version":[{"id":29,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/13\/revisions\/29"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=13"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=13"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=13"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}